Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 4/20 | 0.41 |
| ▸ | NEK2 | P51955 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4543563 | 0.89 | FASN (0.44) | FASNNEK2SMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL4536302 | 0.82 | FASN (0.44) | FASNSMN1; SMN2MEN1ALDH1A1MAPK1 | |
| SCHEMBL4533607 | 0.79 | FASN (0.46) | FASNNEK2SMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL4541813 | 0.77 | FASN (0.44) | FASNNEK2SMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL4536900 | 0.77 | FASN (0.46) | FASNNEK2SMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL14720360 | 0.76 | MGLL (0.32) | MGLL | |
| SCHEMBL4543321 | 0.75 | SIGMAR1 (0.48) | FASNNEK2SMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL15238608 | 0.75 | FASN (0.43) | FASNNEK2SMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL4536336 | 0.74 | FASN (0.65) | FASNNEK2SMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL4538519 | 0.74 | FASN (0.51) | FASNSMN1; SMN2MEN1ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2637660-A1 | FATTY ACID SYNTHASE INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2013-09-18 | — | — | EP | disclosed |
| US-20130237535-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2013-09-12 | — | — | US | disclosed |
| WO-2012064642-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237535-A1 | FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | FASN 1/4885NEK2 2902/4885SMN1; SMN2 4521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.